New York, NY -- (SBWIRE) -- 01/23/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Samson Oil & Gas Limited (ADR) (NYSEMKT:SSN), Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX), Paramount Gold and Silver Corp (NYSEMKT:PZG)
Samson Oil & Gas Limited (ADR) (NYSEMKT:SSN) the stock opened the session at $0.52 but then moved to $0.482. At that price, the stock showed a negative performance of -6.43%. Samson Oil & Gas Limited (Samson), is engaged in exploration and development of oil and natural gas properties in the United States. Samson owns a working interest in each of its three material producing properties, through which it has entered into operating agreements with third parties under which the oil and gas are produced and sold.
Will SSN Get Buyers Even After The Recent Rally? Find Out Here
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) opened the session at $1.68and closed the session at $0.276. The stock showed a positive performance of 4.17% in previous trading session. Traded with volume of 1.14 million shares in the prior session and the average volume of the stock remained 522,830.00 shares. Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company is focused on its research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from the reovirus. This virus has been demonstrated in tumour cells bearing an activated Ras pathway.
For How Long ONCY will fight for Profitability? Read This Trend Analysis report
Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) opened the session at $2.01 and closed the session at $2.09. The stock showed a positive performance of 5.03% in previous trading session. The beta of the stock remained 0.46. Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy.
Why Should Investors Buy CPRX After The Recent Gain? Just Go Here and Find Out
Paramount Gold and Silver Corp (NYSEMKT:PZG) the stock decreased -2.50% and finished the session at $1.17. Traded with volume of 1.12 million shares in the prior session and the average volume of the stock remained 883,352.00 shares. The beta of the stock remained 1.77. Paramount Gold and Silver Corp. (Paramount) is an exploration stage mining company with projects in northern Nevada and Chihuahua, Mexico. Through its wholly owned Mexican subsidiary, Paramount Gold de Mexico S.A. de C.V., the Company owns a 100% interest in the San Miguel property.
Will PZG Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)